Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2837-2841

  Moltó, José ^a,b   Valle, Marta ^b,c   Miranda, Cristina ^a   Cedeño, Samandhy ^a   Negredo, Eugenia ^a   Clotet, Bonaventura ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ETRAVIRINE; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; SILYMARIN; TENOFOVIR; VIRUS RNA;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEARTBURN; HERB; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPEN STUDY; PILL; PRIORITY JOURNAL; SILYBUM MARIANUM; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MILK THISTLE; RITONAVIR; SILYMARIN; SULFONAMIDES;

EID: 84861142616     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00025-12     Document Type: Article

References (46)

1. Ahmed-Belkacem A, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 138:1112-1122.
2. Beckmann-Knopp S, et al. 2000. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol. Toxicol. 86:250-256. (Pubitemid 30413400)
3. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. 2000. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7:273-282. (Pubitemid 30618491)
4. Das S, Roy P, Auddy RG, Mukherjee A. Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity. Int. J. Nanomed. 6:1291-1301.
5. de Maat MM, et al. 2001. Drug interaction between St John's wort and nevirapine. AIDS 15:420-421.
6. De Meyer S, et al. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321. (Pubitemid 40734460)
7. Deng JW, et al. 2008. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm. Res. 25:1807-1814.
8. DiCenzo R, et al. 2003. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 23:866-870. (Pubitemid 36875670)
9. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. 2003. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J. Acquir. Immune Defic. Syndr. 32:287-291. (Pubitemid 36331700)
10. Eurich D, et al Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp. Clin. Transplant.9::1-6.
11. Ferenci P, et al. 2008. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135:1561-1567.
12. Fuhr U, Beckmann-Knopp S, Jetter A, Luck H, Mengs U. 2007. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med. 73: 1429-1435. (Pubitemid 350240497)
13. Garrard J, Harms S, Eberly LE, Matiak A. 2003. Variations in product choices of frequently purchased herbs: caveat emptor. Arch. Intern. Med. 163:2290-2295. (Pubitemid 37310188)
14. Gurley B, et al. 2006. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol. 46:201-213. (Pubitemid 43149297)
15. Gurley BJ, et al. 2006. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab. Dispos. 34:69-74. (Pubitemid 43045694)
16. Gurley BJ, et al. 2005. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22:525-539. (Pubitemid 41003065)
17. Gurley BJ, et al. 2008. Clinical assessment of CYP2D6-mediated herbdrug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and echinacea. Mol. Nutr. Food Res. 52:755-763.
18. Gutmann H, et al. 2006. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med. 72:685-690.
19. Hennessy M, et al. 2002. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. 53:75-82. (Pubitemid 34117742)
20. Hruby K, Csomos G, Fuhrmann M, Thaler H. 1983. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum. Toxicol. 2:183-195. (Pubitemid 13040466)
21. Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 43:375-388.
22. Izzo AA, Ernst E. 2009. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69:1777-1798.
23. Kim YC, et al. 2003. Comparative bioavailability of silibinin in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. 41:593-596. (Pubitemid 37527566)
24. Ladenheim D, et al. 2008. Potential health risks of complementary alternative medicines in HIV patients. HIV Med. 9:653-659.
25. Lee LS, Andrade AS, Flexner C. 2006. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin. Infect. Dis. 43:1052-1059. (Pubitemid 44631108)
26. Littlewood RA, Vanable PA. 2008. Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care. AIDS Care 20:1002-1018.
27. Loguercio C, Festi D. 2011. Silybin and the liver: from basic research to clinical practice. World J. Gastroenterol. 17:2288-2301.
28. Mehrab-Mohseni M, et al. Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. World J. Gastroenterol. 17:1694-1700.
29. Melhem A, et al. 2005. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J. Clin. Gastroenterol. 39:737-742. (Pubitemid 41177097)
30. Mills E, et al. 2005. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur. J. Clin. Pharmacol. 61: 1-7. (Pubitemid 40558272)
31. .Moltó J, et al. 2012. Use of herbal remedies among HIV-infected patients: patterns and correlates. Med. Clin. (Barc.) 138:93-98.
32. Muriel P, Garciapina T, Perez-Alvarez V, Mourelle M. 1992. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol. 12:439-442.
33. Muriel P, Moreno MG, Hernandez Mdel C, Chavez E, Alcantar LK. 2005. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin. Pharmacol. Toxicol. 96:375-380. (Pubitemid 40676591)
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
35. Payer BA, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J. Clin. Virol. 49:131-133.
36. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St John's wort. Lancet 355:547-548. (Pubitemid 30088677)
37. Piscitelli SC, et al. 2002. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 22:551-556. (Pubitemid 34464940)
38. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. 2004. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 54:109-113. (Pubitemid 38264886)
39. Risa KJ, et al. 2002. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. Int. J. STD AIDS 13:706-713.
40. Salmi HA, Sarna S. 1982. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand. J. Gastroenterol. 17:517-521. (Pubitemid 12054336)
41. Sekar V, et al. 2008. Abstr. 15th Conf. Retrovir. Opportunist. Infect., abstr. 769.
42. Sekar VJ, et al. 2007. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir. Ther. 12:509-514. (Pubitemid 47041149)
43. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. 2004. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos. 32:587-594. (Pubitemid 38668150)
44. Valenzuela A, Lagos C, Schmidt K, Videla LA. 1985. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem. Pharmacol. 34:2209-2212. (Pubitemid 15017088)
45. Venkataramanan R, et al. 2000. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab. Dispos. 28: 1270-1273.
46. Zhang S, Morris ME. 2003. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm. Res. 20:1184 -1191.